CXCL8 and renal cell carcinoma: A large study of plasma IL‐8 as a prognostic biomarker in three clinical trials of αPD‐L1 in UC and RCC (n = 1445 patients total) consistently demonstrated that high baseline IL‐8 levels (above the median of the cohort, 15 pg/mL) were associated with shorter OS.37